Veru plans to initiate a Phase 2b “Plateau” study this quarter testing enobosarm, an oral selective androgen receptor modulator, alongside semaglutide in older adults with obesity, with an interim readout expected in Q1 2027. The double-blind, placebo-controlled trial will enroll approximately 200 patients aged 65 and older with BMI ≥35 who are initiating semaglutide, evaluate weight change at 68 weeks as the primary endpoint, and include interim DXA-based analyses of fat and lean mass at 34 weeks. The program builds on Veru’s prior Phase 2b data suggesting that enobosarm preserved lean mass, enhanced fat loss during active weight reduction with semaglutide, and helped prevent weight and fat regain after semaglutide discontinuation. Veru also reported improved quarterly financials, with operating losses reduced and cash rising to $33 million, supporting near-term execution.
The strategic bet is clear: move the obesity conversation from “how much” weight is lost to “what” weight is lost and retained. As GLP-1 monotherapy scales, muscle loss, functional decline, and bone health have emerged as clinically relevant liabilities—particularly in older patients—and weight-loss plateaus are common. The question is whether an oral adjunct that selectively preserves muscle, improves physical function, and potentially protects bone can earn a place alongside incretins, and whether that value will be recognized by payers in a market already bracing for combination regimens from the incumbents.
Timing and regulatory climate favor this attempt. FDA guidance to Veru outlines two potential approval pathways for an enobosarm plus GLP-1 regimen: demonstrate at least a 5% placebo-corrected incremental weight loss at 52 weeks versus GLP-1 alone, or, if weight loss is similar, show a clinically meaningful functional benefit such as preserved physical function. In December 2025, FDA also validated total hip bone mineral density as a surrogate endpoint in postmenopausal osteoporosis, just as large cardiovascular outcomes data and labeling updates highlighted fracture risk signals in GLP-1–treated populations. For patients and HCPs, that alignment reframes quality of weight loss—body composition, function, and bone integrity—as outcomes worth monitoring, not just numbers on a scale. For payers, fracture avoidance and maintained independence in older, high-BMI cohorts translate into potentially quantifiable cost offsets that could justify an adjunct’s premium.
The trial design signals a commercialization thesis. Choosing semaglutide preserves optionality for a future all-oral combination with oral semaglutide, an adherence and access lever that peptide-only stacks cannot easily match. Extending endpoints to 68 weeks addresses the clinical reality of plateaus and maintenance, while embedding DXA, stair-climb, and PROs speaks to payer and guideline bodies increasingly attuned to function and quality of life. Still, market access will hinge on head-to-head incremental value versus GLP-1 alone, safety in a SARM class with historical baggage, and a clear economic story linking composition gains to fewer falls, fractures, and hospitalizations. Medical Affairs teams will need to operationalize DXA-based monitoring, build pragmatic RWE around fractures and functional decline, and educate on sarcopenic obesity in routine practice.
The broader trend is unmistakable: obesity care is shifting toward combination strategies and endpoint pluralism. As big pharma races to embed muscle- or bone-sparing properties into next-gen poly-agonists, small-molecule adjuncts offer a nearer-term, potentially lower-cost overlay to the vast installed base of GLP-1 users. Veru’s cash position suggests a partnering imperative to scale Phase 3 and commercial infrastructure. The inflection point to watch is whether enobosarm can deliver either clear incremental weight loss or unambiguous functional and BMD advantages by 52–68 weeks. If it does, does obesity management standardize into chronic combination regimens optimized for composition, or will integrated multi-agonists render add-ons a transitional step?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
